ECRONICON OPEN ACCESS

EC NEUROLOGY
Review Article

When the Immune System Turns on the Muscles: Exploring the Spectrum of Myopathies with Autoimmune Origins

Ahed J Alkhatib[1,2,3]*

[1]*Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan*

[2]*International Mariinskaya Academy, Department of Medicine and Critical Care, Department of Philosophy, Academician Secretary of Department of Sociology, Jordan*

[3]*Cypress International Institute University, Texas, USA*

***Corresponding Author:** Ahed J Alkhatib, Department of Legal Medicine, Toxicology and Forensic Medicine, Jordan University of Science and Technology, Jordan.

Received: April 17, 2023; **Published:** May 22, 2023

Abstract

Myopathies are a group of disorders in which the body's immune system attacks the muscles, causing weakness and wasting of the affected muscles. This type of myopathy is caused by the immune system. There have been a number of studies conducted with the primary goals of elucidating the underlying mechanisms and coming up with effective treatments for these conditions. The primary objective of this research was to conduct a literature search focusing on recent developments in the understanding of myopathies brought on by the immune system. In conclusion, the findings of these studies shed light on the complexity of myopathies brought on by the immune system as well as the necessity of using personalized approaches in the diagnosis and treatment of these conditions. Additional research is required to better understand the mechanisms that are at play and to develop therapies that are more specifically aimed at treating these conditions.

Keywords: *Myopathies; Immune System; Autoantibodies; Myositis; Immunosuppressive Therapies*

An overview of myopathies caused by the immune system

Immune-mediated myopathies are a group of acquired muscle diseases that include dermatomyositis, necrotizing autoimmune myopathy, overlap myositis, and inclusion body myositis [1,2]. With the exception of inclusion body myositis, many diseases can be effectively treated with medicines that suppress the immune system. A condition known as dermatomyositis is characterized by a rash that appears on the skin as well as a weakness in the muscles that are located proximal to the skin. Perifascicular atrophy, perimysial and perivascular infiltrates of CD4+ T cells, B cells, and plasmacytoid dendritic cells, as well as sarcolemmal overexpression of MHC1, are all found in biopsies taken from affected muscles. The deposition of membrane assault complex on intramuscular capillaries is an early manifestation of dermatomyositis. The cause of the microangiopathy is unknown; however, dermatomyositis manifests itself in this way. Seventy percent of patients who have been diagnosed with dermatomyositis have a specific autoantibody that has been linked to a number of clinical manifestations. Two examples of this category of antibodies are anti-nuclear matrix protein NXP2 antibodies and anti-transcriptional factor 1 (TIF-1) antibodies. There is a correlation between exposure to this and an increased risk of developing cancer.

Significant cutaneous abnormalities such as skin ulcers and interstitial lung disease can develop in patients who have antibodies to the MDA5 gene, which is associated with melanoma differentiation. Antisynthetase syndrome is a form of autoimmune myopathy that has been linked to a number of other diseases that affect the connective tissue. Overlap myositis is a form of myopathy that affects the muscles, and this is a common symptom of the condition. It has been discovered that patients suffering from this condition have autoantibodies that are directed against multiple aminoacyl tRNA synthetases. Patients who are found to have anti-Jo antibodies have an increased risk of developing Raynaud's phenomenon as well as radial finger skin lesions, also known as mechanic's hands. There is also a connection between myopathy and interstitial lung disease. Symptoms of immune-mediated necrotizing myopathy include proximal muscular weakness, elevated levels of creatine kinase, muscle biopsies demonstrating necrosis and regeneration with low or no lymphocytic infiltration, overexpression of MHC1, and membrane-attack complex deposition on non-necrotic fibers. Immune-mediated necrotizing myopathy is a rare form of myopathy that affects the immune system. Muscle biopsies that show little or no lymphocytic infiltration are another way to diagnose immune-mediated necrotizing myopathy. Autoantibodies to signal recognition particle (anti-SRP) or 3-hydroxyl 3-methylglutaryl coenzyme-A reductase (HMGCR), an enzyme that catalyzes the rate-limiting step in cholesterol production, are found in approximately two-thirds of patients. HMGCR is an enzyme that catalyzes the step in cholesterol production that is responsible for the majority of the rate-limiting activity. An enzyme known as HMGCR is responsible for catalyzing the stage of cholesterol production that is most likely to give rise to health complications. Those individuals who have a history of taking statins are the ones who are most likely to have antibodies to HMGCR. On muscle biopsies, patients with inclusion body myositis have CD8+ inflammatory infiltrates as well as rimmed vacuoles, ragged red fibers indicating mitochondrial damage, and aberrant protein aggregates, indicating both an inflammatory and a degenerative process. This is because inclusion body myositis is characterized by a combination of inflammatory and degenerative processes. This is due to the fact that inclusion body myositis is distinguished by a confluence of inflammatory and degenerative processes in the affected muscles. Patients who have been diagnosed with sporadic inclusion body myositis have a 30 - 60% chance of having autoantibodies that are directed against cytosolic 5'-nucleotidase 1 A in their bodies [3,4].

Types of myopathies caused by the immune system

Myopathies are a group of muscular disorders that affect the muscles of the human body that are responsible for movement. These muscles include the skeletal muscles. Mutations in genes, infections, exposure to toxins, and autoimmune diseases are all potential triggers for myopathies. Myopathies that are brought on by the immune system are classified into a subcategory known as immune-mediated myopathies (IMMs). These diseases are distinguished by inflammation as well as damage to the muscle fibers, which ultimately results in a loss of muscle mass and strength. In this article, we will go over the various types of immune-mediated myopathies, their symptoms, diagnosis, and treatment, as well as the most recent research in this area [1].

Inflammation and immune-mediated myopathies

Inflammatory myopathies and non-inflammatory myopathies are the two primary categories that immune-mediated myopathies fall into. There are several different types of immune-mediated myopathies, and they can be divided into these two categories based on their clinical and pathological characteristics [2].

Inflammatory myopathies

Inflammatory myopathies (IM) are a group of autoimmune diseases that primarily affect the muscles and cause inflammation. The three main subtypes of inflammatory myopathies are discussed below.

Dermatomyositis, also known simply as DM, is an extremely uncommon autoimmune condition that can affect both the skin and the muscles. Rash, weakness in the muscles, and difficulty swallowing are some of the symptoms of diabetes mellitus. Diabetes mellitus is frequently linked to a number of other autoimmune conditions, including lupus, rheumatoid arthritis, and scleroderma [5]. Dermatomyositis, also known simply as DM, is an extremely uncommon autoimmune disease that can manifest in either children or adults. Inflamma-

tion of the skin and muscles is one of the hallmarks of diabetes mellitus, which can result in a wide range of symptoms [5]. Among the most typical manifestations of diabetes mellitus are the following:

- A distinctive rash, which typically appears on the face, neck, shoulders, and upper chest Weakness in the muscles, particularly in the proximal muscles (which are the muscles closest to the trunk of the body), which can make it difficult to climb stairs, get up from a chair, or lift objects [6].
- Tiredness as well as a loss of energy [7].
- Difficulty swallowing, which can lead to aspiration pneumonia [8].
- Aspiration pneumonia can be caused by difficulty swallowing.
- Soreness and stiffness in the joints [9].
- Difficulty in drawing a full breath [9].
- Raynaud's phenomenon, in which the extremities, most commonly the fingers and toes, turn white or blue in response to exposure to cold temperatures or stress [10].

DM is classified as an autoimmune disease because it is caused by the immune system of the body attacking healthy cells and tissues in error. It is currently unknown what exactly causes DM, but researchers believe that a number of factors, both genetic and environmental, play a role [11].

DM is frequently linked to a number of other autoimmune conditions, including scleroderma, rheumatoid arthritis, and lupus. According to the findings of some studies, up to twenty-five percent of people who have diabetes also have another autoimmune disease. Some researchers believe that there may be shared genetic or environmental factors that contribute to the development of these conditions [12,13]. It is not clear why DM is linked to other autoimmune diseases, but some researchers believe that there may be shared genetic or environmental factors that contribute to the development of these conditions:

In a nutshell, DM is a rare form of autoimmunity that impacts both the skin and the muscles. This condition is frequently linked to other forms of autoimmunity, such as lupus, rheumatoid arthritis, and scleroderma. It is imperative that you get medical help as soon as you can, whether you are the one experiencing symptoms of diabetes mellitus or you know someone who is.

1. Polymyositis (PM): PM is a rare autoimmune disease that causes muscle inflammation and weakness. The symptoms of PM include difficulty in climbing stairs, getting up from a chair, and lifting objects. PM is often associated with other autoimmune diseases such as scleroderma, lupus, and rheumatoid arthritis [14]. PM is a rare autoimmune disease that causes muscle inflammation and weakness, particularly in the proximal muscles (i.e. those closer to the trunk of the body). The exact cause of PM is not fully understood, but it is believed to be the result of a combination of genetic and environmental factors [15]. PM can occur at any age, but it most commonly affects individuals between the ages of 40 and 60. The symptoms of PM may develop gradually or suddenly and can include progressive muscle weakness, especially in the proximal muscles, difficulty climbing stairs, getting up from a chair, or lifting objects, fatigue, and dysphagia (difficulty swallowing), muscle pain and tenderness, shortness of breath and respiratory weakness. PM is often associated with other autoimmune diseases such as scleroderma, lupus, and rheumatoid arthritis. In fact, up to 30% of individuals with PM also have another autoimmune disease. The co-occurrence of multiple autoimmune diseases is known as "overlap syndrome" [12,13].
2. Inclusion body myositis (IBM): IBM is the most common form of inflammatory myopathy in older adults. It causes muscle weakness and wasting in the muscles of the arms, legs, and throat. IBM is often misdiagnosed as PM or amyotrophic lateral sclerosis (ALS) [16]. Inclusion body myositis (IBM) is a rare autoimmune disease and is the most common form of inflammatory myopathy in individuals over the age of 50. IBM is characterized by muscle weakness and wasting in the muscles of the arms, legs, and throat. The exact cause of IBM is not known, but it is believed to be related to an abnormal immune response in the muscle cells. IBM is

often misdiagnosed as polymyositis (PM) or amyotrophic lateral sclerosis (ALS) due to similarities in symptoms. However, there are some distinguishing features of IBM, such as slow and insidious onset of symptoms, asymmetrical weakness, affecting one side of the body more than the other, involvement of the distal muscles (i.e. those farther from the trunk of the body), such as the muscles of the hands and feet, resistance to standard treatments for PM or other inflammatory myopathies [17-19]. Taken together, IBM is a progressive disease with no known cure, and current treatments only offer limited symptomatic relief. However, ongoing research is exploring potential therapies, such as immune-modulating drugs and gene therapy.

Non-inflammatory myopathies

Myopathies that are immune-mediated but do not result in inflammation are referred to as non-inflammatory myopathies, or NIM for short [20]. The following are the three primary categories of non-inflammatory myopathies:

1. Necrotizing myopathy (NM): NM is a form of muscle wasting and weakness that is caused by a rare form of autoimmune disease. In contrast to IMs, NM does not result in inflammation of the muscle. The inability to perform tasks such as climbing stairs, lifting objects, and getting up from a chair is one of the symptoms of NM [21]. NM is not characterized by inflammation of the muscles, as is the case with the majority of immune-mediated myopathies (IMs). In its place, it is characterized by necrosis of the muscle fibers, also known as the death of muscle fibers, which leads to weakness and wasting of the muscles. The inability to climb stairs, lift objects, or get up from a chair is a common symptom of neuromyelitis optica (NM), which is similar to other conditions that are associated with muscle weakness. Other symptoms may include fatigue, difficulty swallowing (dysphagia), and dyspnea (difficulty breathing) (shortness of breath). In order to confirm the presence of muscle fiber necrosis and rule out other potential causes of muscle weakness, NM is typically diagnosed through a combination of clinical evaluation, blood tests, imaging studies, and muscle biopsies. In most cases, the treatment for NM consists of the use of immunosuppressant medications to lessen the abnormal immune response and supportive measures to keep the muscle strength and function intact [22-25].
2. Anti-synthetase syndrome (ASS): ASS is an uncommon autoimmune disease that causes inflammation in the muscles as well as interstitial lung disease. Weakness in the muscles, pain in the joints, and shortness of breath are some of the symptoms of ASS [26]. Anti-synthetase syndrome, also known as ASS, is a relatively uncommon autoimmune disease that is characterized by inflammation of the muscles as well as interstitial lung disease (ILD). Anti-synthetase antibodies are the specific antibodies that are discovered in the blood of people who are affected by the syndrome. These antibodies are the reason why the syndrome was given its name. Muscle weakness, joint pain, and shortness of breath are the most common symptoms of Acute Symptomatic Sclerosis (ASS), although these symptoms can vary from person to person. Fever, the Raynaud phenomenon, and rashes on the skin are all possible additional symptoms. In terms of diagnosis, a clinical evaluation, laboratory tests, and imaging studies are typically used to confirm the presence of muscle inflammation, immunologic lupus dilatans (ILD), and anti-synthetase antibodies. Typically, this process takes place over the course of several days. Immunosuppressive medications, such as corticosteroids and other immunomodulatory drugs, are typically used in the treatment of acquired systemic sclerosis (ASS), with the goal of reducing the immune response and preventing further damage to the muscles and lungs [27-29].
3. Immune-mediated necrotizing myopathy (IMNM): IMNM is a rare autoimmune disease that causes muscle weakness and wasting. It is characterized by a progressive degeneration of muscle tissue. Unlike NM, IMNM does not result in inflammation of the muscles [22]. The inability to perform tasks such as climbing stairs, lifting objects, and getting up from a chair is one of the symptoms of IMNM. It is true that Immune-Mediated Necrotizing Myopathy, also known as IMNM, is a rare autoimmune disease that leads to the wasting and weakness of muscles. IMNM is distinguished from other types of myositis, such as polymyositis and dermatomyositis, in that it causes necrosis (cell death) in the muscle but does not cause a significant amount of inflammation. The pathology of IMNM has been investigated by a number of studies, and those studies have reported findings that are consistent with necrotizing myopathy. These findings include necrosis and regeneration of muscle fibers, as well as a lack of inflammatory infiltrates [30-32].

For instance, Mammen., *et al*. [30] conducted research in which they examined muscle biopsies taken from patients diagnosed with IMNM. They discovered that necrosis and regeneration were the most prominent histologic features, but there was no significant inflammation present. In line with the findings of the previous study, Allenbach., *et al*. [31] found that muscle biopsies taken from patients with IMNM showed necrosis of muscle fibers accompanied by regeneration, but no evidence of inflammation. There is evidence to suggest that IMNM is associated with specific autoantibodies, such as anti-SRP (signal recognition particle) and anti-HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase) antibodies, which target proteins involved in muscle function. This is in addition to the muscle pathology that has been observed in patients with IMNM [33,34]. Overall, IMNM does not cause significant inflammation in the muscles; however, it is distinguished by the necrosis and regeneration of muscle fibers, in addition to the presence of specific autoantibodies.

Symptoms of immune-mediated myopathies:

The symptoms of immune-mediated myopathies vary from disease to disease and from patient to patient depending on the severity of the condition [35]. However, the following are some of the most frequently experienced symptoms of IMs:

1. Weakness and atrophy of the skeletal muscles Weakness of the skeletal muscles is the most common symptom of IMs. In most cases, the muscles in the arms, legs, and trunk are the ones to suffer from the weakness. In extreme cases, the weakness can affect the muscles that are responsible for breathing and swallowing, which can have serious consequences [35]. Weakness and atrophy of the muscles are two of the most characteristic symptoms of immune-mediated myopathies (IMs). The muscle weakness typically affects the muscles in the arms, legs, and trunk, and its severity can range from mild to severe. The condition is known as myasthenia gravis. In extreme circumstances, the weakness can affect the muscles that are in charge of breathing and swallowing, which can be extremely dangerous. Although the precise mechanisms that cause muscle weakness and wasting in IMs are not fully understood, it is thought that it is related to inflammation and damage to the muscles caused by an abnormal immune response. This theory is based on the fact that IMs are thought to be caused by an abnormal immune response. In order to diagnose IMs, clinical evaluations, blood tests, imaging studies, and muscle biopsies are frequently used in conjunction with one another to determine the particular form of myopathy that is present and to direct treatment. The treatment of muscle weakness and wasting in IMs typically involves a combination of medications to reduce inflammation and modify the immune response, in addition to physical therapy and other supportive measures, with the goal of maintaining muscle strength and function [36-39].
2. Exhaustion Two of the most common symptoms of IMs is exhaustion. It is frequently brought on by a lack of muscle strength and can be severe enough to restrict typical daily activities [39]. One of the most common signs and symptoms of immune-mediated myopathies is fatigue (IMs). It is frequently brought on by the muscle weakness and wasting that goes hand in hand with these conditions, and it can be severe enough to restrict day-to-day activities and negatively affect quality of life. The precise mechanisms that are responsible for fatigue in IMs are not fully understood, but it is believed that it is connected to the metabolic and immune system changes that take place as a result of the disease. In addition, the psychological impact of coping with a chronic condition that is frequently debilitating can contribute to feelings of fatigue and low energy levels. It can be difficult to manage fatigue in IMs, but techniques like physical activity, energy conservation methods, and medications that improve energy levels and reduce inflammation can all be helpful in improving symptoms [37].
3. Pain: Some people who have IMs may experience muscle pain, which is typically at its worst after they have participated in physical activity [35]. One of the symptoms that may be present in some individuals who have immune-mediated myopathies is pain or tenderness in the muscles (IMs). This pain is frequently worse after activity or exercise, and it may be accompanied by a feeling of muscle weakness as well as fatigue. It is not fully understood what causes muscle pain in IMs, but it is thought to be related to inflammation and damage to the muscles, as well as the effects of the immune response on the nervous system and other tissues in the body. The exact cause of muscle pain in IMs is not fully understood. It can be difficult to manage the muscle pain that comes with IMs, but treatments like light exercise, physical therapy, and medications that reduce inflammation and help manage pain can

be helpful in improving symptoms. It is essential to keep in mind that not everyone who has IMs will experience muscle pain, and both the intensity of the pain and the frequency with which it occurs can vary greatly from person to person [36,37].

4. Immune-mediated myopathies typically present themselves with symptoms such as difficulty climbing stairs, getting up from a chair, and lifting objects (IMs). These pursuits call for a certain level of muscular stamina, particularly in the thighs, hips, and core muscles, all of which are frequently weakened by IMs. In more severe cases, the weakness and atrophy of these muscles can make it difficult or even impossible to perform these activities independently, which can have a significant impact on both day-to-day life and quality of life [36].

Summary

Myopathies are a group of diseases in which the body's immune system mistakenly attacks its own muscle tissue, which leads to muscle weakness, inflammation, and damage. These diseases are caused by the immune system. The conditions known as dermatomyositis, polymyositis, and inclusion body myositis are the most common types of immune-mediated myopathies.

The primary goals of research on immune-mediated myopathies have been to gain an understanding of the underlying mechanisms underlying these diseases, to improve diagnostic techniques, and to develop new therapies to treat the symptoms of immune-mediated myopathies and slow the progression of these diseases. Methotrexate and rituximab are two examples of immunosuppressant drugs that have been investigated in recent research for their potential to treat dermatomyositis and polymyositis by lowering inflammation and protecting muscle tissue. Other research has been conducted to investigate the efficacy of new targeted therapies, such as anti-CD20 antibodies and anti-TNF-alpha antibodies, in treating these diseases. Overall, research into myopathies brought on by the immune system is still in its early stages, and scientists have a long way to go before they have a complete understanding of these difficult and frequently debilitating conditions. However, recent progress in understanding their underlying mechanisms and developing new treatments offers hope for improved diagnosis and treatment in the future.

Bibliography

1. Milone M. “Diagnosis and management of immune-mediated myopathies”. *Mayo Clinic Proceedings* 92 (2017): 826-837.
2. Selva-O’Callaghan A., *et al*. “Classification and management of adult inflammatory myopathies”. *The Lancet Neurology* 17 (2018): 816-828.
3. Alkhatib AJ. “Autoimmunity and Diseases”. In: The Role of Microbes in Autoimmune Diseases. Springer, Singapore (2022).
4. Alkhatib AJ. “The Role of Microbes in Autoimmune Diseases”. Springer, Singapore (2022).
5. Dalakas MC. “Inflammatory muscle diseases”. *New England Journal of Medicine* 372.18 (2015): 1734-1747.
6. Mammen AL. “Necrotizing autoimmune myopathies”. *Continuum* (2017): 1682-1697.
7. Liao H., *et al*. “Dermatomyositis: Advances in pathogenesis and therapies”. *Clinical and Experimental Rheumatology* 38.1 (2020): 118-125.
8. O’Connell PG and Rider LG. “Immunopathogenesis of idiopathic inflammatory myopathies”. *Muscle and Nerve* 57.2 (2018): 192-199.
9. Fiorentino DF. “Dermatomyositis”. *Hand Clinics* 34.2 (2018): 175-184.
10. Wigley FM. “Raynaud’s Phenomenon”. *Journal of the American Academy of Dermatology* 46.6 (2002): 914-926.

11. Dalakas MC. "Inflammatory muscle diseases: a critical review on pathogenesis and therapies". *Current Opinion in Pharmacology* 34 (2017): 1-9.

12. Amato AA and Greenberg SA. "Inflammatory myopathies". *Continuum* (2015): 1644-1667.

13. Lundberg IE and Tjärnlund A. "Inflammatory myopathies: diagnosis and classification". *Journal of Internal Medicine* 280.1 (2016): 39-51.

14. Kassardjian CD., *et al*. "A review of autoimmune myopathies and their mimics". *Clinical Neurology and Neurosurgery* 169 (2018): 30-47.

15. Dalakas MC. "Inflammatory muscle diseases". *New England Journal of Medicine* 372.18 (2015): 1734-1747.

16. Allenbach Y and Benveniste O. "Idiopathic inflammatory myopathies in adults: a comparative review". *Autoimmunity Reviews* 18.7 (2019): 693-708.

17. Needham M., *et al*. "Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches". *The Lancet Neurology* 6.7 (2007): 620-631.

18. Lloyd TE and Mammen AL. "Inclusion body myositis: update on pathogenesis and treatment". *Current Opinion in Neurology* 28.5 (2015): 525-530.

19. Dimachkie MM and Barohn RJ. "Inclusion body myositis: update on diagnosis and management". *Neurotherapeutics* 11.4 (2014): 1184-1194.

20. Hilton-Jones D and Miller A. "Non-inflammatory myopathies". *The Lancet* 389.10069 (2017): 987-1002.

21. Nagaraju K and Casciola-Rosen L. "Myopathy with autoantibodies to signal recognition particle". Up To Date (2021).

22. Allenbach Y and Benveniste O. "Immune-mediated necrotizing myopathies: a short review on recent progress". *Journal of Neurology* 266.4 (2019): 862-871.

23. Allenbach Y and Benveniste O. "Necrotizing autoimmune myopathies". *Current Opinion in Neurology* 32.5 (2019): 720-727.

24. Oldroyd A., *et al*. "Necrotizing autoimmune myopathy: a rare and distinct form of idiopathic inflammatory myopathy". *Rheumatology International* 38.8 (2018): 1359-1366.

25. Tiniakou E. "Necrotizing myopathy: recent advances and clinical implications". *Current Opinion in Rheumatology* 32.6 (2020): 569-575.

26. Solomon J., *et al*. "Interstitial lung disease in anti-synthetase syndrome". Up To Date (2021).

27. Betteridge ZE., *et al*. "Novel autoantibodies and clinical phenotypes in adult and juvenile myositis". *Arthritis Research and Therapy* 18.1 (2016): 14.

28. Maturu VN., *et al*. "Interstitial lung disease in idiopathic inflammatory myopathies: approach to diagnosis and management". *Indian Journal of Rheumatology* 14.2 (2019): 107-115.

29. Oddis CV. "Update on the diagnosis and treatment of the idiopathic inflammatory myopathies". *Current Allergy and Asthma Reports* 19.12 (2019): 63.

30. Mammen AL., *et al*. "Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy". *Arthritis and Rheumatology* 64.11 (2012): 3638-3647.

31. Allenbach Y., *et al*. "Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis. "*Expert Review of Clinical Immunology* 10.5 (2014): 615-626.

32. Mammen AL. "Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis". *Annals of the New York Academy of Sciences* 1413.1 (2017): 84-98.

33. Betteridge Z., *et al*. "Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients". *Journal of Rheumatology* 42.1 (2015): 144-149.

34. Allenbach Y., *et al*. "Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin". *Medicine* 95.8 (2016): e2457.

35. Mammen AL. "Myositis-specific autoantibodies: an important tool to support diagnosis of myositis". *The Lancet Neurology* 19.12 (2020): 987-988.

36. Dalakas MC. "Inflammatory muscle diseases". *New England Journal of Medicine* 381.9 (2019): 844-855.

37. Mastaglia FL and Phillips BA. "Inflammatory myopathies: clinical, diagnostic and therapeutic aspects". *Muscle and Nerve* 62.4 (2020): 461-475.

38. Amato AA and Griggs RC. "Unicorns, dragons, polymyositis, and other mythical beasts". *Neurology* 71.4 (2008): 273-274.

39. Katzav A and Pick CG. "Fatigue in autoimmune diseases". *Journal of Neurology* 268.6 (2021): 1870-1879.

Volume SP15 2023